IL163866A0 - 8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredient - Google Patents
8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredientInfo
- Publication number
- IL163866A0 IL163866A0 IL16386603A IL16386603A IL163866A0 IL 163866 A0 IL163866 A0 IL 163866A0 IL 16386603 A IL16386603 A IL 16386603A IL 16386603 A IL16386603 A IL 16386603A IL 163866 A0 IL163866 A0 IL 163866A0
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- active ingredient
- drugs containing
- azaprostaglandin derivative
- azaprostaglandin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002058487 | 2002-03-05 | ||
JP2002216567 | 2002-07-25 | ||
JP2003013447 | 2003-01-22 | ||
PCT/JP2003/002478 WO2003074483A1 (fr) | 2002-03-05 | 2003-03-04 | Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif |
Publications (1)
Publication Number | Publication Date |
---|---|
IL163866A0 true IL163866A0 (en) | 2005-12-18 |
Family
ID=27792041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16386603A IL163866A0 (en) | 2002-03-05 | 2003-03-04 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredient |
Country Status (16)
Country | Link |
---|---|
US (3) | US7402605B2 (xx) |
EP (1) | EP1481976B1 (xx) |
JP (2) | JP4547912B2 (xx) |
KR (1) | KR100704215B1 (xx) |
CN (1) | CN1653046A (xx) |
AU (1) | AU2003211574A1 (xx) |
BR (1) | BR0308166A (xx) |
CA (1) | CA2477715A1 (xx) |
IL (1) | IL163866A0 (xx) |
MX (1) | MXPA04008596A (xx) |
NO (1) | NO20043702L (xx) |
NZ (1) | NZ535024A (xx) |
PL (1) | PL372084A1 (xx) |
RU (1) | RU2306309C2 (xx) |
TW (1) | TW200305425A (xx) |
WO (1) | WO2003074483A1 (xx) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1556347A4 (en) * | 2002-06-10 | 2006-08-09 | Applied Research Systems | GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE |
CA2495917A1 (en) * | 2002-08-28 | 2004-03-11 | Merck Frosst Canada & Co. | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma |
AU2003275838A1 (en) * | 2002-10-25 | 2004-05-13 | Beunard, Jean-Luc | Pyrrolidin-2-on derivatives as ep4 receptor agonists |
WO2004089411A1 (ja) * | 2003-04-03 | 2004-10-21 | Ono Pharmaceutical Co., Ltd. | 脊柱管狭窄症治療剤 |
EP2422814A1 (en) | 2003-07-25 | 2012-02-29 | Ono Pharmaceutical Co., Ltd. | Remedy for cartilage-related diseases |
EP1682127B1 (en) * | 2003-11-14 | 2009-07-29 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
US7833995B2 (en) | 2003-12-05 | 2010-11-16 | Ono Pharmaceutical Co., Ltd. | Blood flow promoters for cauda equina tissues |
WO2005072743A1 (ja) * | 2004-01-30 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 気管支拡張剤 |
JP2006008568A (ja) * | 2004-06-24 | 2006-01-12 | Cyclochem:Kk | IgE抗体抑制剤および食品 |
US7858650B2 (en) | 2004-10-22 | 2010-12-28 | Ono Pharmaceutical Co., Ltd. | Medicinal composition for inhalation |
EP1841733A2 (en) | 2004-11-08 | 2007-10-10 | Allergan, Inc. | Substituted pyrrolidone compounds as prostaglandin ep4 agonists |
MX2007006777A (es) * | 2004-12-06 | 2007-08-06 | Avigen Inc | Ibudilast para tratar dolor neuropatico y sindromes asociados. |
US7635716B2 (en) | 2005-01-14 | 2009-12-22 | Allergan, Inc. | Substituted cyclopentanes or cyclopentanones as therapeutic agents |
NZ560691A (en) * | 2005-03-10 | 2011-03-31 | Allergan Inc | Substituted gamma lactams as therapeutic agents |
CA2610692C (en) * | 2005-06-03 | 2014-11-25 | Ono Pharmaceutical Co., Ltd. | Ep2 agonists which may have an ep3 agonistic effect for regeneration and/or protection of nerves |
WO2007005176A1 (en) * | 2005-06-29 | 2007-01-11 | Allergan, Inc. | Pyrrolidinones for the treatment of glaucoma and ocular hypertension |
US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
US7323591B2 (en) | 2006-01-10 | 2008-01-29 | Allergan, Inc. | Substituted cyclopentanes or cyclopentanones as therapeutic agents |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
US7557095B2 (en) * | 2006-05-12 | 2009-07-07 | Allergan, Inc. | Therapeutic compounds |
US7507833B2 (en) | 2006-08-10 | 2009-03-24 | Allergan, Inc. | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives |
CN101522669B (zh) * | 2006-08-11 | 2013-01-16 | 阿勒根公司 | 治疗用内酰胺 |
US7795287B2 (en) | 2006-09-01 | 2010-09-14 | Allergan, Inc. | Therapeutic substituted hydantoins and related compounds |
EP2269611B1 (en) | 2006-11-16 | 2016-03-23 | Gemmus Pharma Inc. | EP2 and EP4 agonists as agents for the treatment of influenza A viral infection |
KR20080055355A (ko) * | 2006-12-15 | 2008-06-19 | 에스케이케미칼주식회사 | 보관안정성이 우수한 클로피도그렐 함유 포접 복합체 |
AU2007334038A1 (en) * | 2006-12-18 | 2008-06-26 | Allergan, Inc. | Methods and compositions for treating gastrointestinal disorders |
EP2131841B1 (en) * | 2007-01-30 | 2012-08-01 | Avigen, Inc. | Methods for treating acute pain |
WO2008094912A2 (en) * | 2007-01-31 | 2008-08-07 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
CN101657445B (zh) * | 2007-02-15 | 2013-06-05 | 阿勒根公司 | 治疗青光眼或眼内压升高的γ内酰胺 |
EP2123273B1 (en) | 2007-02-16 | 2013-10-23 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for urinary excretion disorder |
US7589213B2 (en) * | 2007-04-27 | 2009-09-15 | Old David W | Therapeutic substituted lactams |
WO2008137012A1 (en) * | 2007-05-03 | 2008-11-13 | Avigen, Inc. | Use of a glial attenuator to prevent amplified pain responses caused by glial priming |
WO2008136519A1 (ja) * | 2007-05-08 | 2008-11-13 | National University Corporation, Hamamatsu University School Of Medicine | Ep4アゴニストを含有してなる細胞傷害性t細胞の活性化剤 |
LT2264009T (lt) | 2008-03-12 | 2019-04-25 | Ube Industries, Ltd. | Piridilaminoacto rūgšties junginys |
US7956055B2 (en) | 2008-03-25 | 2011-06-07 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
JP5524181B2 (ja) * | 2008-04-24 | 2014-06-18 | アラーガン インコーポレイテッド | 治療剤としての置換ガンマラクタム |
WO2009140205A2 (en) | 2008-05-15 | 2009-11-19 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
CN102209719B (zh) | 2008-09-10 | 2014-05-14 | 旭硝子株式会社 | 新型前列腺素i2衍生物 |
JP5300033B2 (ja) | 2009-03-30 | 2013-09-25 | 宇部興産株式会社 | 緑内障の治療又は予防のための医薬組成物 |
PT2441760E (pt) | 2009-06-10 | 2014-01-07 | Ono Pharmaceutical Co | Composto com actividade de contracção muscular do detrusor e actividade de relaxação muscular do esfíncter uretral |
GB2474120B (en) * | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
TWI555744B (zh) | 2010-03-08 | 2016-11-01 | Kaken Pharma Co Ltd | Novel EP4 agonists |
JP2014513077A (ja) | 2011-04-05 | 2014-05-29 | アミラ ファーマシューティカルス,インコーポレーテッド | 線維症、疼痛、癌、ならびに呼吸器、アレルギー性、神経系または心血管疾患の治療に有用な3−または5−ビフェニル−4−イルイソキサゾールに基づく化合物 |
TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
EP2874620B1 (en) | 2012-07-19 | 2016-10-12 | Cayman Chemical Company, Incorporated | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions |
CA2882732C (en) | 2012-08-31 | 2021-03-30 | Ono Pharmaceutical Co., Ltd. | A 2-[(2-{(1r,5r)-2-oxo-5-[(1e,4s)-7,8,8-trifluoro-4-hydroxy-4-methyl-1,7-octadiene-1-yl]cyclopentyl}ethyl)thio}-1,3-thiazole-4-carboxylic acid 4-piperidinemethanol salt and crystals thereof |
DK2989098T3 (en) | 2013-03-15 | 2017-08-28 | Cayman Chemical Co Inc | LACTAM RELATIONS AS EP4 RECEPTOR SELECTIVE AGONISTS FOR USING THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS |
WO2014144610A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
AU2014244926A1 (en) | 2013-03-28 | 2015-11-12 | Ube Industries, Ltd. | Substituted biaryl compound |
WO2015009991A2 (en) | 2013-07-19 | 2015-01-22 | Cayman Chemical Company, Inc. | Methods, systems, and compositions for promoting bone growth |
US9540357B1 (en) | 2014-07-31 | 2017-01-10 | Allergan, Inc. | 15-aryl prostaglandins as EP4 agonists, and methods of use thereof |
KR102376248B1 (ko) * | 2015-01-09 | 2022-03-21 | 오노 야꾸힝 고교 가부시키가이샤 | 삼환성 스피로 화합물 |
WO2017173024A1 (en) * | 2016-03-30 | 2017-10-05 | AyuVis Research LLC | Novel compositions and therapeutic methods |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS511461A (en) | 1974-06-24 | 1976-01-08 | Tanabe Seiyaku Co | 88 azapurosutansanjudotainoseiho |
GB1529852A (en) | 1975-03-21 | 1978-10-25 | Labaz | 8-azaprostaglandins and process for the preparation thereof |
NL7604330A (nl) | 1975-04-28 | 1976-11-01 | Syntex Inc | Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten. |
DE2556326A1 (de) | 1975-12-13 | 1977-06-23 | Hoechst Ag | Neue pyrrolidone und verfahren zu ihrer herstellung |
IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
EP0471201A1 (de) | 1990-07-21 | 1992-02-19 | Hoechst Aktiengesellschaft | Neue Oxazolidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen |
US5280034A (en) * | 1991-08-23 | 1994-01-18 | E. R. Squibb & Sons, Inc. | Bis-heterocyclic prostaglandin analogs |
IT1254373B (it) | 1992-05-29 | 1995-09-14 | Eteroprostanoidi, procedimento per la loro preparazione e loro impiegoterapeutico. | |
US5362879A (en) * | 1993-04-15 | 1994-11-08 | Bristol-Myers Squibb Company | 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation |
TW401408B (en) * | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
CN1413190A (zh) | 1999-12-22 | 2003-04-23 | 辉瑞产品公司 | 治疗骨质疏松的ep4受体选择性激动剂 |
DK1132086T3 (da) | 2000-01-31 | 2006-08-28 | Pfizer Prod Inc | Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt |
US20010056060A1 (en) | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
WO2002024647A1 (fr) | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine |
IL155368A0 (en) * | 2000-11-27 | 2003-11-23 | Pfizer Prod Inc | Ep4 receptor selective agonists in the treatment of osteoporosis |
ES2254726T3 (es) * | 2001-07-16 | 2006-06-16 | F. Hoffmann-La Roche Ag | Analogos de prostaglandina como agonistas receptores de ep4. |
EP1408961B1 (en) | 2001-07-16 | 2007-07-11 | F. Hoffmann-La Roche Ag | 2 pyrrolidone derivatives as prostanoid agonists |
HU230421B1 (hu) * | 2001-07-23 | 2016-05-30 | Ono Pharmaceutical Co., Ltd | Csonttömegveszteséggel kapcsolatos betegségek kezelésére adható, EP4 agonistát tartalmazó gyógyászati készítmények és hatóanyagként alkalmazható vegyületek |
US20040204590A1 (en) * | 2001-12-03 | 2004-10-14 | Ogidigben Miller J. | Ep4 receptor agonist, compositions and methods thereof |
EP1461026A2 (en) * | 2001-12-03 | 2004-09-29 | Merck & Co., Inc. | Method for treating ocular hypertension |
US7858650B2 (en) * | 2004-10-22 | 2010-12-28 | Ono Pharmaceutical Co., Ltd. | Medicinal composition for inhalation |
-
2003
- 2003-03-04 EP EP03743585A patent/EP1481976B1/en not_active Expired - Lifetime
- 2003-03-04 BR BR0308166-4A patent/BR0308166A/pt not_active IP Right Cessation
- 2003-03-04 KR KR1020047013858A patent/KR100704215B1/ko not_active IP Right Cessation
- 2003-03-04 JP JP2003572953A patent/JP4547912B2/ja not_active Expired - Fee Related
- 2003-03-04 US US10/506,536 patent/US7402605B2/en not_active Expired - Fee Related
- 2003-03-04 RU RU2004129584/04A patent/RU2306309C2/ru not_active IP Right Cessation
- 2003-03-04 AU AU2003211574A patent/AU2003211574A1/en not_active Abandoned
- 2003-03-04 CA CA002477715A patent/CA2477715A1/en not_active Abandoned
- 2003-03-04 TW TW092104500A patent/TW200305425A/zh unknown
- 2003-03-04 WO PCT/JP2003/002478 patent/WO2003074483A1/ja active Application Filing
- 2003-03-04 NZ NZ535024A patent/NZ535024A/en unknown
- 2003-03-04 PL PL03372084A patent/PL372084A1/xx not_active Application Discontinuation
- 2003-03-04 IL IL16386603A patent/IL163866A0/xx unknown
- 2003-03-04 CN CNA03810251XA patent/CN1653046A/zh active Pending
- 2003-03-04 MX MXPA04008596A patent/MXPA04008596A/es not_active Application Discontinuation
-
2004
- 2004-09-03 NO NO20043702A patent/NO20043702L/no not_active Application Discontinuation
-
2008
- 2008-06-13 US US12/139,260 patent/US7683094B2/en not_active Expired - Fee Related
-
2009
- 2009-11-17 JP JP2009262122A patent/JP2010077142A/ja not_active Withdrawn
-
2010
- 2010-01-07 US US12/683,609 patent/US8026273B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MXPA04008596A (es) | 2004-12-06 |
NZ535024A (en) | 2006-10-27 |
TW200305425A (en) | 2003-11-01 |
KR20040095264A (ko) | 2004-11-12 |
EP1481976A4 (en) | 2006-01-18 |
JP2010077142A (ja) | 2010-04-08 |
RU2306309C2 (ru) | 2007-09-20 |
PL372084A1 (en) | 2005-07-11 |
CN1653046A (zh) | 2005-08-10 |
AU2003211574A1 (en) | 2003-09-16 |
EP1481976A1 (en) | 2004-12-01 |
JPWO2003074483A1 (ja) | 2005-06-30 |
BR0308166A (pt) | 2005-01-18 |
US20050124577A1 (en) | 2005-06-09 |
WO2003074483A1 (fr) | 2003-09-12 |
KR100704215B1 (ko) | 2007-04-10 |
RU2004129584A (ru) | 2005-05-27 |
CA2477715A1 (en) | 2003-09-12 |
NO20043702L (no) | 2004-12-03 |
US20090042885A1 (en) | 2009-02-12 |
US8026273B2 (en) | 2011-09-27 |
US7683094B2 (en) | 2010-03-23 |
JP4547912B2 (ja) | 2010-09-22 |
EP1481976B1 (en) | 2012-11-07 |
US7402605B2 (en) | 2008-07-22 |
US20100113388A1 (en) | 2010-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL163866A0 (en) | 8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredient | |
IL164699A0 (en) | Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient | |
HK1086830A1 (en) | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | |
IL161940A0 (en) | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | |
IL202190A0 (en) | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | |
AU3076700A (en) | 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient | |
IL181783A0 (en) | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | |
IL162548A0 (en) | 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same | |
AU2002354054A1 (en) | Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient | |
IL166482A0 (en) | Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same | |
PL376154A1 (en) | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | |
HUP0401963A3 (en) | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | |
IL163846A0 (en) | Multiple-component solid phases containing at least one active pharmaceutical ingredient | |
ZA200502496B (en) | Ester compound and medicinal use thereof. | |
AU2002226674A1 (en) | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient | |
EP1604971A4 (en) | PROCESS FOR ADDING ACTIVE CHARCOAL IN WATER PURIFICATION AND WATER PURIFICATION METHOD | |
HUP0303948A2 (hu) | Szájban diszpergálódó szilárd gyógyszerforma | |
AU2001277738A1 (en) | Piperidine derivatives and drugs containing these derivatives as the active ingredient | |
EP1541174A4 (en) | MEDICINE OR COSMETIC PRODUCT | |
EP1234834A4 (en) | 1,3,4-OXADIAZOLINE-2-ONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING SUCH DERIVATIVES USEFUL AS ACTIVE INGREDIENT | |
AU2003201892A1 (en) | Skin perparation for external use containing purpuricenus temminckii frass as the active ingredient | |
AU2003252361A1 (en) | Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient | |
IL161768A0 (en) | Carboxylic acid derivative compounds and drugs containing the same as the active ingredient | |
AU2003207180A1 (en) | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | |
AU2003208064A1 (en) | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient |